EAST RUTHERFORD, N.J., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation CBM, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that it is investing approximately $3 million to increase the capacity and efficiency of one of its cGMP manufacturing facilities at its site in Paullo, Milan, Italy. The investment will include the installation of a new 12,000 liter reactor, as well as reconfiguration of the layout to allow for the replacement of existing centrifuges with new, more efficient equipment.
The 1,350 sq. m (approx. 14,500 sq. ft) facility manufactures intermediates and APIs under GMP conditions, and this investment is part of a campaign by Cambrex of continuous improvement across its global network of manufacturing sites.
"This investment not only increases the overall capacity and capabilities of the facility, but also its flexibility, allowing us to work more efficiently," commented Aldo Magnini, Managing Director, Cambrex Milan. "The generics portfolio is an important aspect of Cambrex's business strategy and we have undertaken a number of improvements and expansions at the site to ensure we have the ability to meet the future demands of the industry."
In June 2018, Cambrex announced an expansion to the R&D laboratories at Paullo, and in 2017 increased the site's capabilities to handle and manufacture highly potent APIs.
Cambrex currently manufactures over 70 generic APIs which are produced to cGMP standards. The Milan site comprises seven production departments, supported by a pilot plant, kilo-scale plant and development and analytical laboratories.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), finished dosage forms, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing. For more information, please visit www.cambrex.com.
Contact:
Alex Maw
Director, Marketing and Communications
Tel: +44 7803 443 155
Email: alex.maw@cambrex.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
